Taysha Gene Therapies (NASDAQ:TSHA) will release its quarterly earnings report on Tuesday, 2025-08-12. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate Taysha Gene Therapies to report an earnings per share (EPS) of $-0.07.
The market awaits Taysha Gene Therapies’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Performance in Previous Earnings
During the last quarter, the company reported an EPS beat by $0.01, leading to a 5.47% increase in the share price on the subsequent day.
Here’s a look at Taysha Gene Therapies’s past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.09 | -0.08 | -0.09 | -0.17 |
| EPS Actual | -0.08 | -0.07 | -0.10 | -0.09 |
| Price Change % | 5.0% | -2.0% | 3.0% | 12.0% |
Market Performance of Taysha Gene Therapies’s Stock
Shares of Taysha Gene Therapies were trading at $2.72 as of August 08. Over the last 52-week period, shares are up 21.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Views on Taysha Gene Therapies
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Taysha Gene Therapies.
The consensus rating for Taysha Gene Therapies is Buy, derived from 8 analyst ratings. An average one-year price target of $8.38 …